Based in Taiwan, Elixiron is a startup founded in 2018. Brouky records 1 investor associated with the company.
Elixiron develops precision immunotherapies targeting neuroinflammation, autoimmune diseases, and cancer, with multiple drug candidates in clinical trials and an mRNA drug development platform.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.